英文名称
Dolutegravir Sodium Salt-D4
分子式
C20 D4 H14 F2 N3 Na O5
Standards; Isotopic Labeled Analogues; Pharmaceutical/API Drug Impurities/Metabolites;
Dolutegravir is currently in Phase III clinical trials for the treatment of HIV infection. Dolutegravir has been shown to potently inhibit HIV replication in cells such as peripheral blood mononuclear cells (PBMCs), MT-4 cells and CIP4 cells infected with a self-inactivating PHIV lentiviral vector.